P486 ALIROCUMAB EFFECTIVENESS AND RAPIDITY IN ACHIEVING AND MAINTAINING TARGET LDL CHOLESTEROL VALUES IN PATIENTS AT VERY HIGH CARDIOVASCULAR RISK, ALSO ASSESSING ITS EFFECTS ON TRIGLYCERIDE AND HDL CHOLESTEROL VALUES

Abstract Introduction Still too few patients (pts)after an acute cardiocerebrovascular(CeVD) event reach LDL–C values recommended by guidelines even in therapy with statins and Ezetimibe(Eze),thus maintaining a high risk of new cardiovascular(CV)episodesPurpose: To evaluate long follow–up the effectiveness rapidity Alirocumab(Ali)in attainment maintenance LD–C target pts at very only Eze because they are intolerant to Methods Our case studies consist 72 which 80% male(58)and 20% female(14),with average age 61.9 y,90.2% were hypertensive,34.7% diabetic 15.2% peripheral arteriopathy;5.5% had chronic kidney disease (CKD stage III) In history 65.2% ACS 34.7% CeVD.84.7% while 15.3% association PUFA N–3. The value was 169.2 mg/dl. follow up 24 months (mths) clinical checks 3,6,12 24. dosage Ali varied from 150 75 mg relation basal achieve rapid reduction least 50%.Triglyceride (Tg) HDL–C also evaluated Results At 3 mths 52.24%, recording 34,7% cases greater 65%; 6 51.18%; 12 51.36% 52.47%. 37 who started mg, base 183.0 mg/dl, showed C–LDL 59.04%, 58.45%, 65.05%, 55.76%. ESC reached for 42.10% mths; 52.63% 6; 63.15% 73.68% 5.5% CKD mths, 65.22% 6, 57.49% 53.95% Tg study 3.55% increase 8.75% 1.65% 7.95% 4.55% 3.69% 10.97% 7.82% Conclusions have confirmed reducing CV reaching set management risk. increasing HDL–C, accordance 2019 it not possible confirm values.